Advertisement

cid1450

SABCS 2020: First Immunotherapy Combo Well-Tolerated

In an interim analysis of the first immunotherapy combination phase 1b trial with trastuzumab deruxtecan, safety results showed nivolumab with trastuzumab deruxtecan was well tolerated in patients with HER2-positive or HER2-low...

Read More

SABCS 2020: Update from the DESTINY-Breast01 trial

In an updated analysis of the phase 2 DESTINY-Breast01 study, women with HER2-positive metastatic breast cancer taking antibody-drug conjugate trastuzumab deruxtecan continued to demonstrate favorable efficacy data, durable...

Read More

SABCS 2020: Updates on Phase 3 PENELOPE-B

The collaborative Phase 3 PENELOPE-B will be presented at SABCS 2020. No unexpected safety signals were observed. Phase 3 PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival (iDFS) in...

Read More

PhysQuiz Answers! ACR Convergence 2020

Thank you for taking our quiz on PsA from results presented at ACR Convergence 2020! How did you do? 1) DMARD-naïve patients achieving Routine Assessment of Patient Index Data 3 (RAPID3) and the Clinical Disease Activity for...

Read More

For latest news and updates
Email-id is invalid